MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.

Study Overview

• Status: Completed
• Conditions: Lateral Canthal Lines; Glabellar Lines
• Intervention / Treatment: Drug: MT10109L; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 425
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 4E1
      • Dr. Jean Carruthers Cosmetic Surgery Inc.
    • Vancouver, British Columbia, Canada, V6H 4E1
      • Pacific Derm
  • Ontario
    • Burlington, Ontario, Canada, L7N 3N2
      • Dermetics Cosmetic Dermatology
    • Richmond Hill, Ontario, Canada, L4B 1A5
      • Nectar Research Group Inc.
• Germany
  • Cologne, Germany, 50996
    • Hautzentrum Koln - Cologne Dermatology
  • Muenchen, Germany, 80333
    • Hautok and Hautok-cosmetics
  • Oberursel, Germany, 61440
    • MediCorium Zentrum fuer Dermatologie und Aesthetik
  • Wuppertal, Germany, 42287
    • CentroDerm GmbH
  • Hessen
    • Darmstadt, Hessen, Germany, 64283
      • Rosenpark Research
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85255-4134
      • Clear Dermatology & Aesthetics Center
  • California
    • Solana Beach, California, United States, 92075-2228
      • Art of Skin MD
  • Florida
    • Bradenton, Florida, United States, 34209-5642
      • Susan H. Weinkle, MD
  • Louisiana
    • New Orleans, Louisiana, United States, 70130-4353
      • Etre Cosmetic Dermatology and Laser Center
  • New York
    • New York, New York, United States, 10028
      • Dermatology and Laser Surgery Center of New York
    • Rochester, New York, United States, 14623
      • Skin Search of Rochester Inc.
  • North Carolina
    • Raleigh, North Carolina, United States, 27612-8106
      • M3 Wake Research Inc.
    • Wilmington, North Carolina, United States, 28403
      • Wilmington Dermatology Center
  • Ohio
    • Dublin, Ohio, United States, 43016
      • Aventiv Research Inc.
  • Texas
    • Austin, Texas, United States, 78759
      • DermResearch Inc.
    • Austin, Texas, United States, 78746-4720
      • Westlake Dermatology & Cosmetic Surgery - Westlake

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

-Female participants must not be pregnant or planning to get pregnant and willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.

Exclusion Criteria:

• Known immunization or hypersensitivity to any botulinum toxin serotype.
• Any medical condition that may put the participant at increased risk with exposure to MT10109L including diagnosed myasthenia gravis, Eaton Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
• History of facial nerve palsy.
• Any uncontrolled systemic disease.
• Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study intervention).
• Anticipated need for surgery or overnight hospitalization during the study.
• Prior exposure to botulinum toxin of any serotype for any reason.
• Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery).
• Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation.
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
• Females who are pregnant, nursing, or planning a pregnancy during the study.
• Participants who plan for an extended absence away from the immediate area of the study site that would preclude them from returning for all protocol-specified study visits.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MT10109L Dose 1 + Placebo; MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.	Drug: MT10109L; MT10109L will be injected into either the LCL, or both the LCL and GL.; Other Names: NivobotulinumtoxinA; Drug: Placebo; Placebo will be injected into either the GL, or both the LCL and GL.
Experimental: MT10109L Dose 1 + MT10109L Dose 2; MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.	Drug: MT10109L; MT10109L will be injected into either the LCL, or both the LCL and GL.; Other Names: NivobotulinumtoxinA
Placebo Comparator: Placebo; Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.	Drug: Placebo; Placebo will be injected into either the GL, or both the LCL and GL.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of LCL Severity at Maximum Smile at Day 30	The outcome measured is the percentage of participants who had a ≥2-grade improvement from baseline LCL severity at maximum smile according to investigator and participant FWS ratings at Day 30. Both the INVESTIGATOR AND PARTICIPANT evaluate the LCL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe. The primary endpoint is achieved and recorded as a count only when BOTH INVESTIGATOR AND PARTICIPANT assess the improvement in FWS from baseline to be ≥ 2-grade improvement. Therefore, the primary endpoint is the proportion/percentage of participants who meet the dual assessment threshold of ≥2-grade improvement from baseline.	Day 30

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Percentage of Responders for INVESTIGATOR Assessments of Lateral Canthal Lines (LCL) Severity at Maximum Smile Using the Facial Wrinkle Scale With Photonumeric Guide (FWS)	The outcome here only considers the INVESTIGATOR assessments (excludes the participant assessment). The investigator evaluates the participant's LCL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. A Responder was defined as one achieving a ≥2-grade improvement from baseline at maximum smile at Day 30.	Day 30
The Duration of Lateral Canthal Lines (LCL) Treatment in Participants Who Achieved a Rating of ≥ 2-grade Improvement From Baseline in LCL Severity at Maximum Smile at Day 30 According to Investigator Assessments Using the FWS	The investigator evaluates the participant's LCL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.	Day 1 (first treatment) to Day 180
The Percentage of Participants Reporting Mostly Satisfied/Very Satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 for Lateral Canthal Lines (LCL)	The Satisfaction Question 5 grades facial line treatment satisfaction on a 5-point scale (-2 to 2) where -2=Very dissatisfied and 2=Very satisfied.	Day 60
The Percentage of Responders for Investigator Assessments of Lateral Canthal Lines (LCL) Severity at Rest Using the Facial Wrinkle Scale (FWS)	The investigator evaluates the participant's LCL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. Among Participants Who Were Rated At least Mild at Rest at Baseline, where a Responder was Defined as Achieving a ≥1-grade Improvement from Baseline at Day 30. The outcome measured here is the proportion of participants who achieved a ≥1-grade improvement from baseline LCL severity at rest based on investigator FWS rating.	Day 30
Number of Patients Who Experienced a Treatment Emergent Adverse Event (TEAEs)	This section focuses primarily on TEAEs, i.e., AEs that started or worsened after the first dose of study intervention and within 30 days after the last dose. The safety analyses were conducted in the Safety population. Unless otherwise noted, safety results refer to TEAEs.	AEs that started or worsen after the first dose of study intervention and within 30 days after the last dose.
Mean Change From Baseline in Systolic Blood Pressure (BP)	The outcome reported here is the mean change in Systolic BP from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Diastolic Blood Pressure (BP)	The outcome reported here is the mean change in Diastolic BP from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Pulse Rate	The outcome reported here is the mean change in Pulse Rate from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Respiratory Rate	The outcome reported here is the mean change in Respiratory Rate from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - Mean Heart Rate	The outcome reported here is a mean change in mean heart rate from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - PR Interval	The outcome reported here is a mean change in PR interval from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QRS Duration	The outcome reported here is a mean change in QRS duration from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QT Interval	The outcome reported here is a mean change in QT interval from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcB Interval	The outcome reported here is a mean change in QTcB interval from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcF Interval	The outcome reported here is a mean change in QTcF interval from baseline to study exit.	Baseline to Day 360
Mean Change From Baseline in Electrocardiogram (ECG) Parameters - RR Interval	The outcome reported here is a mean change in RR interval from baseline to study exit.	Baseline to Day 360
Number of Participants With Binding and Neutralizing Antibodies	Only samples that tested positive in the binding antibody confirmatory assay were evaluated for neutralizing antibodies. The participants with positive neutralizing antibodies are only shown.	Baseline to Day 360

Collaborators and Investigators

• Sponsor: Medy-Tox
• Investigators: Study Director: SangMi Park, Medytox Inc

Study record dates

Study Major Dates

• Study Start (Actual): November 5, 2018
• Primary Completion (Actual): March 5, 2020
• Study Completion (Actual): January 25, 2021

Study Registration Dates

• First Submitted: November 5, 2018
• First Submitted That Met QC Criteria: November 5, 2018
• First Posted (Actual): November 7, 2018

Study Record Updates

• Last Update Posted (Actual): July 17, 2023
• Last Update Submitted That Met QC Criteria: July 12, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: MT10109L-006; 2014-005302-38 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No